GSK Reports the EMA’s Acceptance of MAA for Blenrep Combinations to Treat Multiple Myeloma
Shots:
- The EMA has accepted MAA of Blenrep in addition to bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone (PomDex) for treating r/r multiple myeloma
- The submission was based on interim data of two P-III trials, DREAMM-7 assessing Blenrep + BorDex vs daratumumab + BorDex and DREAMM-8 assessing Blenrep + PomDex vs bortezomib + PomDex for treating r/r MM
- The studies reached their 1EPs, depicting improved PFS with a trend favoring OS that was insignificant during analysis, its evaluation is underway; improvements in the 2EPs were also observed such as deeper & durable responses. Safety profile was consistent in both
Ref: GSK | Image: GSK
Related News:- GSK Highlights P-III (DREAMM-8) Study Data of Blenrep Plus Pomalidomide and Dexamethasone for R/R Multiple Myeloma at ASCO 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
